Isaac Barchas Sells 16,906 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 16,906 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $24.20, for a total value of $409,125.20. Following the completion of the sale, the director owned 108,504 shares of the company’s stock, valued at $2,625,796.80. The trade was a 13.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Trading Down 1.6%

Shares of NASDAQ IMNM opened at $24.01 on Thursday. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The firm has a market capitalization of $2.72 billion, a PE ratio of -10.09 and a beta of 2.07. The business has a 50-day moving average price of $21.00 and a two-hundred day moving average price of $21.86.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Research analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current year.

Institutional Investors Weigh In On Immunome

Large investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new position in Immunome in the 1st quarter worth $60,000. Strs Ohio bought a new position in Immunome during the fourth quarter valued at about $64,000. Assetmark Inc. increased its stake in Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after acquiring an additional 1,442 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Immunome in the 4th quarter valued at approximately $121,000. Finally, BNP Paribas Financial Markets raised its holdings in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IMNM. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Immunome in a research note on Wednesday, May 13th. Barclays started coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a research note on Friday, June 12th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.